which will be marketed as Bydureon BCise (exenatide 2mg prolonged-release suspension). The new authorisation has been granted for a single-dose, pre-filled pen device that requires no titration ...

AstraZeneca Plc's AZN Bydureon BCise (exenatide 2 mg prolonged-release suspension for injection) is indicated for type-2 diabetes. Novo Nordisk A/S' NVO semaglutide is approved as Ozempic and ...

Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...

AstraZeneca has had a setback to its ambitions in diabetes, after Bydureon failed to show cardiovascular benefits to patients. The FDA now obliges companies with diabetes products to conduct large ...

Data Sources: PubMed was searched (to December 5, 2011) using the terms exenatide, liraglutide, albiglutide, and lixisenatide. The search was limited to studies published in English and conducted ...

The 2025 MG 4 EV has got a few changes in dimensions and the overall design MG has taken over the electric vehicle market in China and is now heading towards a global influence with the MG 4 EV ...

MG might have a history of making small sports cars but ‘new’ MG – the one owned by Chinese automotive giant SAIC – is very much focused on affordable, practical electric cars. So, what on ...

The Tata Punch EV offers a higher claimed range of 365 km compared to the 332 km offered by the Windsor EV. However, when tested in the real world, both EVs delivered almost the same driving range ...

The MGS5 EV takes the brand’s electric SUV range to new heights thanks to its combination of space, standard equipment and range. It also feels appropriately tuned for UK roads and is surprising ...

Diabetes management and weight-loss drug Mounjaro has been launched in India by makers Eli Lilly, following approval from the drug regulator. This has come amid rising cases of obesity and ...

Acquisition includes world-leading in vivo delivery platform with potential to transform cell therapy AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology ...